Overexpression of PAPP‐A in ovarian cancer cell lines triggers tumorigenesis and cellular invasion [9], and targeting PAPP‐A using a monoclonal antibody reverses platinum resistance in ovarian cancer [8]. This evidence concerns the gene PAPPA and ovarian carcinoma.